Introduction
Gastric cancer remains the fourth most commonly diagnosed cancer globally and the second most common cause of cancer mortality worldwide [1, 2] . Transforming growth factor β (TGF-β) can act as a suppressor or promoter of cancer progression [3] [4] [5] . These ligands signal through the heteromeric complex of transmembrane serine/threonine kinases, the type I and type II receptors (TGFRI and TGFRII), and activate both the Smad family of transcription factors and non-Smad signaling pathways [6] . TGF-β has a dual role in cancer: It limits proliferation in epithelial cells and early-stage cancer cells, whereas in late-stage cancer, it accelerates cancer progression and metastasis [7, 8] . In the cancer niche, TGF-β can be produced and secreted into the extracellular environment by both cancer cells and host cells such as lymphocytes, macrophages and dendritic cells [9] [10] [11] .
Epithelial-to-mesenchymal transition (EMT) occurs in normal physiological processes essential for embryogenesis, tissue morphogenesis and wound healing but is also tightly linked to pathological conditions including fibrosis and cancer progression [12] [13] [14] [15] [16] [17] [18] [19] . During EMT, epithelial cells typically lose their epithelial characteristics, including cell polarity and cell-cell contact, and acquire a spindle-shaped migrating phenotype. The key event in EMT is the switch of E-cadherin to N-cadherin, which renders the single cell more motile and invasive [20] [21] [22] [23] . TGF-β is a major inducer of EMT [24, 25] . Several transcription factors including the zinc finger transcription factors Snail, Slug and Zeb play active roles guiding the EMT process. TGF-β-induced EMT has been suggested to be associated with development and progression of gastric cancer.
MicroRNAs (miRNAs) are small (20-30 nucleotides) noncoding RNAs that posttranscriptionally regulate gene expression through canonical base pairing between the miRNA seed sequence (nucleotides 2-8 at the 5ʹ end) and the complementary sequence in the 3ʹ untranslated region (3ʹUTR) of the target mRNA [26] [27] [28] . The net effect of these events elicits either translational repression or degradation of targeted mRNAs. Recently, several studies have implicated aberrant miRNA expression in the development and metastatic progression of mammary tumors [29] . miRNA-181 family members are the most upregulated miRNAs in gastric cancer. miRNA-181 was initially identified as a hematopoietic lineage modulator. The significant roles of miR-181 in cancer were then revealed by various studies [30] [31] [32] . It has been reported that miR-181b was highly overexpressed in gastric tumors compared to normal gastric tissue and therefore this miRNA holds great potential as a prognostic biomarker in late stage gastric cancer. miRNA-181b was also associated with multi drug resistance by targeting BCL2. However, the mechanism underlying the role of TGF-β-induced miRNA-181b in the tumorigenesis and metastasis of gastric cancer has not been fully elucidated. Additionally, the direct target gene for miRNA-181b involved in TGF-β-induced EMT needs to be identified.
Smads are recognized as downstream intracellular proteins in the signaling pathway of TGF-β, which is mediated through a heteromeric complex of two types of transmembrane receptors, TGF-β receptor type I and II [6] . Smad4 is a central mediator of TGF-β intracellular signaling [33] . However, the requirement of Smad4 in TGF-β-induced EMT and gastric cancer metastasis remains unclear. In this article, we report the contribution of miRNA-181b to TGF-β-induced EMT in vitro. By investigating the phenotypic changes and alterations in TGF-β signaling responses following Smad4 knockdown using RNAi approaches in gastric cancer cells, we show a critical stimulatory function for Smad4 in TGF-β-driven gastric cancer progression.
Materials and Methods

Cell culture and reagents
The human gastric cancer cell lines MKN-28, SGC-7901, HGC-27, AGS and HEK 293T were obtained from our institute. Cells were cultured in Dulbecco's modified Eagle's medium (Hyclone, Logan, UT, United States) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco, CA, United States). All cells were cultured at 37°C in a humidified incubator with 5% CO 2 .
miRNA mimic and inhibitor HGC-27 cells were transfected with miRIDIAN miRNA-181b mimic or mirCURY LNATM miRNA-181b inhibitor using Lipofectamine TM 2000 according to the manufacturer's protocol. After 24-48 h, cells were incubated with TGF-β as stated above.
Wound healing assay
Gastric cell lines were cultured in six-well plates (seeding density 1×10 6 cells/well). Confluent cell monolayers were disrupted by standardized wound scratching using a sterile 200 µl pipette tip and incubated in culture medium with 1% FBS without or with 5 ng/ml TGF-β for 48 h. Migration of cells into the bare area and recovery of the monolayer were monitored for 48 h by a phase contrast microscope and digitally photographed (Nikon Diaphot 300; Nikon, Tokyo, Japan).
Transwell invasion assay
Analyses of tumor cell migration and invasion were carried out using transwell chambers (Corning, United States). After 48 h transfection with miRNA-181b mimic or inhibitor, 2 × 10 5 HGC-27 or AGS cells in serum-free medium were collected and seeded in an upper chamber containing a non-coated 8 µm membrane. Next, 500 µL medium with 20% FBS were added to the lower chamber. For the invasion assay, chambers were coated with extracellular Matrigel (BD Biosciences, United States). Cells were cultured at 37°C in a humidified incubator with 5% CO 2 . Non-migrating or non-invading cells in the upper chamber were removed with a cotton swab and cells that had migrated to or invaded the bottom chamber were fixed and stained with 0.1% crystal violet. Nine fields at ×100 magnification were randomly selected and cell numbers counted. The results were averaged among three independent experiments.
Real-time quantitative PCR
Total RNA was extracted from gastric cancer cells (each experiment contained three repeats per group) by homogenization and lysis in TriPure reagent (Roche Applied Science, Mannheim, Germany) using a high-speed homogenizer. The concentration and purity of mRNA were evaluated using a Nano-Drop 2000 spectrophotometer (Thermo Fisher Scientific, MA, United States). Real-time quantitative PCR (qPCR) was performed following reverse transcription using a Roche LC 480 system with SYBR ® Premix (TaKaRa, Inc., Dalian, China). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. Data were analyzed by comparison Ct (2 -ΔΔCt ) method and expressed as fold change compared to GAPDH. The relative level of mature miRNA-181b in gastric cells was calculated with respect to U6 RNA (internal control). Each sample was analyzed in triplicate. , anti-phospho Smad2/3 (Ab63399, Abcam) and anti-GAPDH (Ab8245, Abcam). The immunoreaction was visualized using an enhanced chemiluminescence detection kit (Amersham, London, UK), exposed to X-ray film, and quantified by densitometry with a video documentation system (Gel Doc 2000, Bio-Rad).
Smad4 knockdown cell lines
The target siRNAs against human Smad4 (GenBank, NM_005359.5) for RNAi were designed as follows: siSmad4, 5'-GCACAACACAACACAACACAACACAAGGTTGGTTGCTAAAA-3' and control RNAi sequence, 5'-TTCTCCCCGAACAACAACGTGTCACCACCACGT-3'. The lentiviral vector system was purchased from Clontech. This vector system includes three plasmids, the pLVX-U6-puro vector, psPAX and pMD2G. The targeting sequence was subcloned into the pLVX-U6-puro vector, which contained the U6 promoter and puromycin gene (puro). The resulting lentiviral vector containing Smad4 shRNA was named RNAi-Smad4, and its sequence was confirmed by PCR and sequencing. The lentiviral vector containing the negative control sequence for Smad4 shRNA (RNAi-NC) with a non-silencing sequence was used as the infection control for lentiviral vector production and cell infection. Lentiviral vectors were produced by transient transfection of HEK293 cells according to standard protocol as previously reported [22, 23] . The HEK293 cell line was supplemented with 10% FBS and when subconfluent was transfected with 1800 μl DNA solution: 10 μg LV-shSmad4, 10 μg psPAX and 10 μg pMD2G. All virus stocks were produced by Lipofectamine-mediated transfection. After transfection for 48 h, cell supernatants containing viral particles were filtered using a 0.45-μm Steriflip vacuum filtration system (Millipore) and concentrated by ultracentrifugation at 25,000 rpm at 4˚C. The titer of the virus was tested according to the expression level of GFP. The day before infection, HGC-27 cells were seeded on dishes with a confluence of 30%-40%. On the day of infection, the HGC-27 cells were infected by packaged lentiviral particles. Parallel non-infected HGC-27 cells were observed simultaneously. Cells were cultured in normal growth medium for 72 h after infection. Transfection with RNAi-NC as infection control was performed as described previously. Cells were subsequently propagated in selection medium containing puromycin.
Luciferase assay
To confirm the targeting between miR-181b and the Timp3 messenger RNA 3ʹUTR, a luciferase assay was used. Part of the wild type 3ʹUTR (WT-3ʹUTR) and mutated 3ʹUTR (Mut-3ʹUTR) of Timp3 messenger RNA, containing the putative miR-181b or mutated miR-181b binding sites, were synthesized and inserted downstream from a luciferase reporter gene in a pGL3 plasmid (Promega, San Luis Obispo, CA, United States). HGC-27 cells were seeded in 24-well plates (8 × 10 4 cells per well) and the next day transfected with 300 ng of the WT or Mut 3ʹUTR luciferase reporter construct, together with a miR-181b or a scrambled precursor (final concentration 20 nM; Dharmacon, Lafayette, CO, United States). Each well was co-transfected with 50 ng of the renilla plasmid pGL3 (Promega) as an internal transfection control. Cells were collected 48 h after transfection, and luciferase activity was measured with a dual-luciferase reporter assay (Promega). Luciferase activity was normalized to Renilla luciferase activity and expressed as the ratio between the luciferase activity of the WT-3ʹUTR plasmid and the Mut-3ʹUTR plasmid. Every luciferase assay experiment was repeated at least three times.
Statistical analysis
Data were expressed as means ± SEM. Statistical significance was determined using ANOVA or repeated ANOVA for multiple comparisons or repeated measurements. Significant differences between two mean values were estimated using Student's t-test. A P value < 0.05 was considered statistically significant.
Results
Effect of TGF-β on HGC-27 and AGS cell migration, invasion and EMT
EMT may contribute to the metastatic potential of tumor cells. Previous studies [15] [16] [17] [18] have demonstrated that TGF-β can induce EMT in tumor cells. EMT is characterized by a clear switch to spindle shape morphology, accompanied by downregulation of E-cadherin and upregulation of Vimentin, Zeb1 and Snail1. HGC-27 and AGS cell lines were selected that maintain a stable epithelial morphology in the absence of TGF-β. Treatment of these two cell lines with TGF-β (5 ng/ml) for 48 h resulted in a strong enhancement of cell migration and invasion by transwell invasion assays (Fig. 1A) and wound healing, respectively (Fig.  1B) . Consistently, qPCR analysis showed the induction of Vimentin, Zeb1 and Snail1 and a reduction in E-cadherin mRNA expression (Fig. 1C) .
Expression of miRNA-181b induced by TGF-β in gastric cancer cells
Recently, several studies [27, 28, 30, 34, 35] have implicated aberrant miRNA expression in the development and metastatic progression of mammary tumors. These studies reported that miR-181 expression was dramatically and selectively upregulated in metastatic breast tumors, particularly triple-negative breast cancers, and was highly predictive for decreased overall survival in human breast cancer patients. We therefore focused on miR-181 family members in our study for their potential function in gastric cancer as downstream effectors of TGF-β signaling. As shown in Fig. 2 , gastric cancer cells (MKN28, SGC-7901, AGS and HGC-27) treated with TGF-β showed increasing expression of pre-miRNA-181b and mature miRNA-181b by qPCR analysis. 
miRNA-181b is involved in TGF-β-mediated migration, invasion and EMT
To study the cellular function of miRNA-181b in gastric cancer, we transfected miRNA181b mimic, inhibitor or siRNA duplexes with non-specific sequences as NC into HGC-27 cells with or without TGF-β treatment. miRNA-181b levels were effectively elevated by transfection of the mimic and decreased by transfection of the inhibitor (data not shown). Inhibition of miRNA-181b significantly suppressed TGF-β-induced HGC-27 cell invasion compared with control cells (P < 0.05, Fig. 3A) , but had no effect on normal HGC-27 cells. However, the in vitro scratch wound-healing assay showed that miRNA-181b inhibition significantly suppressed both TGF−β−induced and normal HGC-27 cell migration (P < 0.05, Fig. 3B ). Interestingly, the over-expression of miRNA-181b only promoted the migration and invasion of normal but not TGF-β-induced HGC-27 cells. Consistently, F-actin staining showed changes in the morphology of HGC-27 cells (Fig. 3C ) and qPCR analysis (Fig. 3D) showed that miRNA-181b inhibition significantly suppressed the EMT of TGF-β-induced HGC-27 cells, evaluated by mRNA expression of Vimentin, Zeb1, Snail1 and E-cadherin (P < 0.05, Fig. 3D ). These results suggested that miRNA-181b is a regulator of TGF-β-induced migration, invasion and EMT in HGC-27 cells.
Inactivation of TGFRII attenuates TGF-β-induced miRNA-181b expression
TGF-β superfamily ligands bind to a type II receptor, which recruits and phosphorylates a type I receptor. The type I receptor then phosphorylates receptor-regulated Smads (such as Smad2) which can now bind the common-mediator (co)-Smad Smad4. In order to investigate the role of the Smad2/3 pathway in the upregulation of miRNA-181b in response to TGF-β, HGC-27 cells were treated with SD-208, a TGFRII inhibitor, which blocked TGF-β signaling as determined by suppression of Smad2 phosphorylation (Fig. 4A) . Furthermore, treatment with SD-208 also blocked TGF-β-induced expression of pre-miRNA-181b (Fig. 4B) and mature miRNA-181b (Fig. 4C) as demonstrated by qPCR analysis. These results suggested /ml; 4, 12, 24 and 48 h) . All values represent mean±SEM from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. the corresponding group. 
that the upregulation of miRNA-181b in response to TGF-β requires the Smad2/3 signaling pathway
Smad4 is required for TGF-β-induced miRNA-181b expression in the early stage of TGF-β induction
Receptor-activated Smads (Smad2 and Smad3 for TGF-β) are phosphorylated in SXSmotives in their C-terminals, where after they form complexes with the co-Smad Smad4. In order to investigate the contribution of Smad2/3/4 complexes in TGF-β-induced upregulation of miRNA-181b, we created a lentivirus-mediated stable Smad4 knockdown HGC-27 cell line, in which the extent of Smad4 knockdown was >75% (Fig. 5A) , while the level of phosphoSmad2 remained unchanged as shown by western blot analysis (Fig. 5B) . Furthermore, Smad4 knockdown blocked TGF-β-induced expression of pre-miRNA-181b (Fig. 5C ) from 4-24 h, and still showed a weak effect at 48 h as demonstrated by qPCR analysis. For the mature miRNA-181b transcript (Fig. 5D ), Smad4 knockdown blocked expression from 4-12 h but only partially blocked expression from 24-48 h. These results suggested that the upregulation of miRNA-181b in response to TGF-β partially required the activation of the type I receptor of TGF-β and the formation of Smad2/3/4 complexes.
Timp3 is a direct and functional target of miR-181b in gastric cancer cells
To explore the potential target of miR-181b involved in TGF-β induction, we investigated whether miR-181b could regulate several reported targets (ATM, Bcl2, CREB1, CYLD and Timp3) in HGC-27 gastric cancer cells. We transfected miRNA-181b mimic, inhibitor or siRNA duplexes with non-specific sequences as NC into HGC-27 cells with or without TGF-β treatment. Only Timp3 expression was regulated by miR-181b. Compared with the corresponding control, the level of Timp3 expression was significantly suppressed by miR181b mimic and was further suppressed with TGF-β treatment (Fig. 6A) . Moreover, Timp3 expression was upregulated by miRNA-181b inhibitor with or without TGF-β (Fig. 6A) .
We further performed luciferase reporter assays to determine whether miR-181b could directly target the 3ʹUTR of Timp3 in GC cells. The target sequence in the Timp3 WT-3ʹUTR or Mut-3ʹUTR was cloned into a luciferase reporter vector (Fig. 6B and C) . HGC-27 cells were then transfected with the WT or Mut 3ʹUTR vector and miRNA-181b mimic. The results showed a significant decrease in luciferase activity when compared with miR-NC (Fig. 6B) . In contrast, the activity of the Mut 3ʹUTR vector was unaffected by simultaneous transfection with miR-181b mimic. The results suggested that Timp3 was a direct target of miR-181b in GC cells.
To examine the functional relationship between miR-181b and Timp3, we analyzed whether Timp3 can counteract the biological effect of TGF-β-induced miR-181b. We evaluated whether ectopic expression of Timp3 could rescue the suppressive effect of miR- recently, the miR-181 family has been implicated in regulating specific steps in the TGF-β-induced metastatic cascade. Because metastasis is the major cause of death for gastric cancer patients, it stands to reason that defining the molecular mechanisms whereby miRNAs have an impact on metastasis may provide novel opportunities to treat metastatic gastric cancers. The miR-181 family contains four members (i.e., miRNAs 181a-d), all of which house identical seed sequences, suggesting that this miRNA family may exhibit redundancy in targeting mRNAs such as ATM, Bcl2, Creb1, CYLD and Timp3 [32, [38] [39] [40] . These targets regulated by miR-181b suggest that the function of miR-181b may be unique, depending on the type of tumor and cellular context. However, the exact mechanism through which the signaling pathway controls the expression of miRNA-181 family members remains to be determined.
Two distinct mechanisms have been reported in the regulation of TGF-β-induced miRNA expression. The downstream effector Smads were reported to bind and activate the promoter of miRNA-155 [41, 42] . However, in the regulation of miR-21, Smad2/3 binds to the primary transcript of miR-21 by interacting with the Drosha processing complex to facilitate the maturation of miR-21 [43] . In the present study, in order to investigate which mechanism is involved in the regulation of TGF-β-induced miRNA-181b expression, we examined the contribution of Smad2/3 phosphorylation via the selective inhibition of TGFRII by SD-208. The TGF-β-induced precursor and mature miRNA-181b were partially inhibited after the treatment with SD-208, suggesting that regulation occurs at the transcriptional level. In the Smad2/3 pathway, to activate the promoter of miRNA-181b, Smad4 is essential for the formation of the Smad2/3/4 complex and translocation into the nucleus following TGF-β stimulation [44, 45] . Smad4 knockdown using lentivirus-mediated shRNA partially blocked TGF−β−induced precursor and mature miRNA-181b, consistent with results following treatment with SD-208, suggesting that the TGF-β-Smad2/3/4 pathway contributes to the regulation of TGF-β-induced miRNA-181b at the transcriptional level.
As there is usually an inverse relationship between the expression of miRNA and their targets, the identification of Timp3 as a target of miR-181b is of considerable interest. Timp3, an inhibitor of metalloprotease, induces apoptosis and inhibits angiogenesis, cell migration and invasion [46] .
In conclusion, this study shows the contribution of the TGF-β-Smad2/3/4 pathway in the regulation of TGF-β-induced miRNA-181b at the transcriptional level and offers a molecular mechanism for the potential role of TGF-β-induced miR-181b in EMT through decreased expression of Timp3.
